KISQALI 200 mg/1 (Ribociclib TABLET, FILM COATED) 200 mg/1

KISQALI 200 mg tablets are a prescription medication used in cancer treatment. This film-coated tablet is manufactured by Novartis Pharmaceuticals Corporation in the USA.

Strength

200 mg/1

Pack Size

3 BLISTER PACK in 1 CARTON (0078-0867-42) / 14 TABLET, FILM COATED in 1 BLISTER PACK (0078-0867-14)

Manufacturer / TM Owner

Novartis Pharmaceuticals Corporation

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

KISQALI 200 mg tablets are commonly used in combination with other medications for the treatment of certain types of cancer. The primary use of ribociclib is in the management of advanced breast cancer. Patients often wonder, 'What is KISQALI used for?' This medication is typically prescribed for specific cancer types and is taken orally.

Side Effects

Common effects of KISQALI 200 mg tablets may include fatigue, nausea, and diarrhea. Some users may experience hair loss or changes in appetite. It's important to note that individual responses to the medication can vary.

Precautions & Warnings

KISQALI 200 mg tablets should be handled with care and stored as directed. It is essential to follow the prescription guidelines provided by your healthcare provider. Always inform your doctor about any other medications you are taking to avoid potential interactions.

Avoid Interactions

KISQALI 200 mg tablets may interact with certain medications, including those that affect liver enzymes. It is advisable to avoid alcohol while taking this medication. Always consult your healthcare provider before starting any new medication.

References

Frequently Asked Questions

KISQALI 200 mg tablets are used in combination with other medications for the treatment of certain types of cancer, primarily advanced breast cancer.

KISQALI 200 mg tablets are taken orally, typically once a day. Follow the specific instructions provided by your healthcare provider.

Common side effects may include fatigue, nausea, diarrhea, hair loss, and changes in appetite. Individual responses can vary.

It is generally advisable to avoid alcohol while taking KISQALI 200 mg tablets to prevent potential interactions.

Store KISQALI 200 mg tablets at room temperature, away from moisture and heat. Keep them in their original packaging.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.